Literature DB >> 24835327

Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries.

Jennifer P Lane1, Laura E L Perkins2, Alexander J Sheehy1, Erica J Pacheco3, Michael P Frie4, Byron J Lambert1, Richard J Rapoza1, Renu Virmani3.   

Abstract

OBJECTIVES: Using intravascular ultrasound (IVUS) and histomorphometry, this study sought to evaluate the potential of nonatherosclerotic porcine coronary arteries to undergo progressive lumen gain and a return of pulsatility after implantation with an everolimus-eluting bioresorbable vascular scaffold (BVS).
BACKGROUND: Unique benefits such as lumen gain and restored vasomotion have been demonstrated clinically after treatment with BVS; however, a more rigorous demonstration of these benefits with a randomized clinical trial has not yet been conducted.
METHODS: Seventy nonatherosclerotic swine received 109 everolimus-eluting BVS and 70 everolimus-eluting metal stents randomized among the main coronary arteries. Arteries were evaluated in vivo by angiography and IVUS and post-mortem by histomorphometry at time points from 1 to 42 months.
RESULTS: From 1 to 6 months, both BVS- and everolimus-eluting metal stent-implanted arteries demonstrated stable lumen areas (LAs). From 12 months to 42 months, there was a progressive increase in the LA of arteries implanted with a BVS as assessed by histomorphometry and IVUS. This lumen gain in the implanted segment corresponded to an increase in the reference vessel LA. Normalization in the in-segment LA (LA:reference vessel LA) was observed qualitatively by angiography and quantitatively by IVUS. Additionally, BVS-implanted arteries demonstrated restored in-segment pulsatility on the basis of IVUS assessment of the differences in the mid-scaffold area between end-diastole to end-systole.
CONCLUSIONS: Starting at 12 months, BVS-implanted porcine coronary arteries underwent progressive lumen gain and showed restored pulsatility. These benefits demonstrated preclinically may translate into improvements in long-term clinical outcomes for patients treated with BVS compared with conventional drug-eluting stents.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  animals; bioresorbable scaffold; coronary artery imaging; pathology

Mesh:

Year:  2014        PMID: 24835327     DOI: 10.1016/j.jcin.2013.11.024

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  11 in total

Review 1.  The Current Literature on Bioabsorbable Stents: a Review.

Authors:  Wally A Omar; Dharam J Kumbhani
Journal:  Curr Atheroscler Rep       Date:  2019-11-25       Impact factor: 5.113

Review 2.  Bioresorbable Polymers and Stent Devices.

Authors:  Payam Dehghani
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-02

3.  Everolimus-Eluting Bioresorbable Vascular Scaffold in Real World Practice - A Single Center Experience.

Authors:  Huai-Wen Liang; Hsien-Li Kao; Yen-Hung Lin; Juey-Jen Hwang; Mao-Shin Lin; Fu-Tien Chiang; Chii-Ming Lee; Chih-Fan Yeh; Tzung-Dau Wang; Cho-Kai Wu; Lian-Yu Lin; Chia-Ti Tsai; Ying-Hsien Chen
Journal:  Acta Cardiol Sin       Date:  2017-05       Impact factor: 2.672

4.  Bioresorbable vascular scaffolds-what does the future bring?

Authors:  Jacek Bil; Robert J Gil
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

Review 5.  Bioresorbable Scaffold-Based Controlled Drug Delivery for Restenosis.

Authors:  Belay Tesfamariam
Journal:  J Cardiovasc Transl Res       Date:  2018-10-26       Impact factor: 4.132

6.  Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model.

Authors:  Carlos M Campos; Yuki Ishibashi; Jeroen Eggermont; Shimpei Nakatani; Yun Kyeong Cho; Jouke Dijkstra; Johan H C Reiber; Alexander Sheehy; Jennifer Lane; Marika Kamberi; Richard Rapoza; Laura Perkins; Hector M Garcia-Garcia; Yoshinobu Onuma; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2015-01-28       Impact factor: 2.357

7.  Impact of Coronary Atherosclerosis on Bioresorbable Vascular Scaffold Resorption and Vessel Wall Integration.

Authors:  Yanping Cheng; Marco Ferrone; Qing Wang; Laura E L Perkins; Jennifer McGregor; Björn Redfors; Zhipeng Zhou; Richard Rapoza; Gerard B Conditt; Aloke Finn; Renu Virmani; Grzegorz L Kaluza; Juan F Granada
Journal:  JACC Basic Transl Sci       Date:  2020-06-03

Review 8.  Vascular restoration therapy and bioresorbable vascular scaffold.

Authors:  Yunbing Wang; Xingdong Zhang
Journal:  Regen Biomater       Date:  2014-10-20

9.  Fractional flow reserve-guided coronary angioplasty using paclitaxel-coated balloons without stent implantation: feasibility, safety and 6-month results by angiography and optical coherence tomography.

Authors:  Tudor C Poerner; Corinna Duderstadt; Björn Goebel; Daniel Kretzschmar; Hans R Figulla; Sylvia Otto
Journal:  Clin Res Cardiol       Date:  2016-07-05       Impact factor: 5.460

10.  Early experience and favorable clinical outcomes of everolimus-eluting bioresorbable scaffolds for coronary artery disease in Korea.

Authors:  Osung Kwon; Jung-Min Ahn; Do-Yoon Kang; Se Hun Kang; Pil Hyung Lee; Soo-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Cheol Whan Lee; Seong-Wook Park; Duk-Woo Park; Seung-Jung Park
Journal:  Korean J Intern Med       Date:  2017-11-07       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.